A detailed history of Rhumbline Advisers transactions in Atossa Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 122,218 shares of ATOS stock, worth $108,774. This represents 0.0% of its overall portfolio holdings.

Number of Shares
122,218
Previous 123,039 0.67%
Holding current value
$108,774
Previous $187,000 39.04%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 30, 2025

SELL
$0.94 - $1.62 $771 - $1,330
-821 Reduced 0.67%
122,218 $114,000
Q3 2024

Nov 12, 2024

SELL
$1.09 - $1.52 $13,166 - $18,360
-12,079 Reduced 8.94%
123,039 $187,000
Q2 2024

Aug 01, 2024

BUY
$1.03 - $2.1 $139,171 - $283,747
135,118 New
135,118 $160,000
Q2 2022

Aug 11, 2022

SELL
$0.85 - $1.28 $120,615 - $181,632
-141,900 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$1.11 - $1.74 $11,408 - $17,883
10,278 Added 7.81%
141,900 $177,000
Q4 2021

Feb 10, 2022

SELL
$1.6 - $3.27 $5,387 - $11,010
-3,367 Reduced 2.49%
131,622 $211,000
Q3 2021

Nov 12, 2021

BUY
$2.89 - $6.4 $13,351 - $29,568
4,620 Added 3.54%
134,989 $440,000
Q2 2021

Aug 05, 2021

BUY
$1.52 - $8.62 $198,160 - $1.12 Million
130,369 New
130,369 $824,000

Others Institutions Holding ATOS

About ATOSSA THERAPEUTICS, INC.


  • Ticker ATOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 126,624,000
  • Market Cap $113M
  • Description
  • Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...
More about ATOS
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.